secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0001787306-24-000090
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis stockholders elect three directors, ratify EY, approve say-on-pay at 2024 annual meeting
--------------------------------------------------------------------------------

- All three Class I director nominees elected: Terrie Curran (77.2M for), Halley Gilbert (75.8M for), Keith R. Leonard Jr. (59.3M for).
- Ratification of Ernst & Young as auditor for FY2024 passed with 95,949,963 votes for, 6,661 against.
- Non-binding advisory vote on named executive officer compensation approved: 56,906,215 for, 26,716,602 against.
- Meeting held June 14, 2024; record date April 22, 2024 with 115,524,989 shares outstanding and entitled to vote.
- Broker non-votes of 12,428,038 on director election and say-on-pay proposals, none on auditor ratification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730624000090/0001787306-24-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730624000090/arqt-20240614.htm
  HTML page:      https://secwatch.observer/filing/0001787306-24-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer